Press release
Scleroderma Pipeline 2025: Mechanism of Action, Route of Administration, and Clinical Trial Insights Explored by DelveInsight | Bayer, Novartis, GSK, Boehringer Ingelheim, Celgene Corp., Johnson & Johnson, Prometic Life Sciences
"Scleroderma Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Scleroderma Market.
The Scleroderma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Scleroderma Pipeline Report: https://www.delveinsight.com/sample-request/scleroderma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Scleroderma treatment therapies with a considerable amount of success over the years.
• Scleroderma companies working in the treatment market are Genentech, AnaMar AB, Acceleron Pharma, Boehringer Ingelheim, Vedotin Seagen, Horizon Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, and others, are developing therapies for the Scleroderma treatment
• Emerging Scleroderma therapies in the different phases of clinical trials are- RO7303509, AM 1476, MK-2225, BI 685509, Brentuximab, HZN-825, MT-0551, and others are expected to have a significant impact on the Scleroderma market in the coming years.
• In November 2024, Zura Bio Limited (Nasdaq: ZURA), a clinical-stage immunology company focused on developing innovative dual-pathway antibodies for autoimmune and inflammatory conditions, has submitted a protocol under its active Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA). The protocol pertains to a Phase 2 study of tibulizumab, a humanized tetravalent bispecific dual antagonist antibody targeting both IL-17A and BAFF, intended for the treatment of systemic sclerosis (SSc) in adult patients.
Scleroderma Overview
Scleroderma is a chronic autoimmune disease that causes the hardening and thickening of the skin and connective tissues. It can also affect internal organs, blood vessels, and the immune system, leading to complications ranging from skin changes to organ dysfunction.
Get a Free Sample PDF Report to know more about Scleroderma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/scleroderma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Scleroderma Drugs Under Different Phases of Clinical Development Include:
• RO7303509: Genentech
• AM 1476: AnaMar AB
• MK-2225: Acceleron Pharma
• BI 685509: Boehringer Ingelheim
• Brentuximab: Vedotin Seagen
• HZN-825: Horizon Pharmaceuticals
• MT-0551: Mitsubishi Tanabe PharmaCorporation
Scleroderma Route of Administration
Scleroderma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Scleroderma Molecule Type
Scleroderma Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Scleroderma Pipeline Therapeutics Assessment
• Scleroderma Assessment by Product Type
• Scleroderma By Stage and Product Type
• Scleroderma Assessment by Route of Administration
• Scleroderma By Stage and Route of Administration
• Scleroderma Assessment by Molecule Type
• Scleroderma by Stage and Molecule Type
DelveInsight's Scleroderma Report covers around 50+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Scleroderma product details are provided in the report. Download the Scleroderma pipeline report to learn more about the emerging Scleroderma therapies
https://www.delveinsight.com/sample-request/scleroderma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Scleroderma Therapeutics Market include:
Key companies developing therapies for Scleroderma are - Boehringer Ingelheim International GmbH, Celgene Corporation, Johnson & Johnson Services, Inc., Prometic Life Sciences Inc., Kadmon Holdings Inc., Emerald Health Pharmaceuticals, Cytori Therapeutics Inc., Bayer AG, F. Hoffman La Roche Ltd, arGentis Pharmaceuticals LLC, GlaxoSmithKline PLC (GSK), Novartis AG, and others.
Scleroderma Pipeline Analysis:
The Scleroderma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Scleroderma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Scleroderma Treatment.
• Scleroderma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Scleroderma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Scleroderma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Scleroderma drugs and therapies
https://www.delveinsight.com/sample-request/scleroderma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Scleroderma Pipeline Market Drivers
• Pharmaceutical and Biotechnology Industries striving on the development of new therapy, increased Awareness among people related to the disease are some of the important factors that are fueling the Scleroderma Market.
Scleroderma Pipeline Market Barriers
• However, higher healthcare cost, adverse effects associated with the drugs and other factors are creating obstacles in the Scleroderma Market growth.
Scope of Scleroderma Pipeline Drug Insight
• Coverage: Global
• Key Scleroderma Companies: Genentech, AnaMar AB, Acceleron Pharma, Boehringer Ingelheim, Vedotin Seagen, Horizon Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, and others
• Key Scleroderma Therapies: RO7303509, AM 1476, MK-2225, BI 685509, Brentuximab, HZN-825, MT-0551, and others
• Scleroderma Therapeutic Assessment: Scleroderma current marketed and Scleroderma emerging therapies
• Scleroderma Market Dynamics: Scleroderma market drivers and Scleroderma market barriers
Request for Sample PDF Report for Scleroderma Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/scleroderma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Scleroderma Report Introduction
2. Scleroderma Executive Summary
3. Scleroderma Overview
4. Scleroderma- Analytical Perspective In-depth Commercial Assessment
5. Scleroderma Pipeline Therapeutics
6. Scleroderma Late Stage Products (Phase II/III)
7. Scleroderma Mid Stage Products (Phase II)
8. Scleroderma Early Stage Products (Phase I)
9. Scleroderma Preclinical Stage Products
10. Scleroderma Therapeutics Assessment
11. Scleroderma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Scleroderma Key Companies
14. Scleroderma Key Products
15. Scleroderma Unmet Needs
16 . Scleroderma Market Drivers and Barriers
17. Scleroderma Future Perspectives and Conclusion
18. Scleroderma Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Scleroderma Market https://www.delveinsight.com/report-store/scleroderma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Scleroderma-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Latest Reports:
• Prediabetes Market: https://www.delveinsight.com/report-store/prediabetes-market
• Scoliosis Market: https://www.delveinsight.com/report-store/scoliosis-market
• Psoriasis Market: https://www.delveinsight.com/report-store/psoriasis-market
• Tendinitis Market: https://www.delveinsight.com/report-store/tendonitis-market
• Vascular Closure Devices Market: https://www.delveinsight.com/report-store/vascular-closure-devices-market
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Hydrocephalus Market: https://www.delveinsight.com/report-store/hydrocephalus-market
• Hemophilia A Market: https://www.delveinsight.com/report-store/hemophilia-a2030-market
• Herpes Simplex Virus Market: https://www.delveinsight.com/report-store/genital-herpes-market
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Scleroderma Pipeline 2025: Mechanism of Action, Route of Administration, and Clinical Trial Insights Explored by DelveInsight | Bayer, Novartis, GSK, Boehringer Ingelheim, Celgene Corp., Johnson & Johnson, Prometic Life Sciences here
News-ID: 4054206 • Views: …
More Releases from DelveInsight Business Research
NK Cell Therapy Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emergi …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Nk Cell Therapy pipeline constitutes 140+ key companies continuously working towards developing 160+ Nk Cell Therapy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Nk Cell Therapy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.…
Cough in Idiopathic Pulmonary Pipeline 2025: FDA Approvals, Therapies, Clinical …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Cough in Idiopathic Pulmonary Fibrosis pipeline constitutes 5+ key companies continuously working towards developing 5+ Cough in Idiopathic Pulmonary Fibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Cough in Idiopathic Pulmonary Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical…
Cryopyrin-Associated Periodic Syndrome Pipeline 2025: Clinical Trials Overview, …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Cryopyrin-Associated Periodic Syndrome pipeline constitutes 4+ key companies continuously working towards developing 4+ Cryopyrin-Associated Periodic Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Cryopyrin-Associated Periodic Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.…
Diabetic Gastroparesis Pipeline 2025: Key Developments, Emerging Therapies, and …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Diabetic Gastroparesis pipeline constitutes 6+ key companies continuously working towards developing 8+ Diabetic Gastroparesis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Diabetic Gastroparesis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetic Gastroparesis Market.
The Diabetic…
More Releases for Scleroderma
Scleroderma Therapeutics Market 2018-2028 Growth, Opportunity And Trends
Global Scleroderma Therapeutics Market: Overview
Global scleroderma therapeutics market is experiencing a major growth in coming years. The growth of the market is majorly driven by rising off-label use of drugs approved for symptomatic indications, for instance rheumatoid arthritis. Moreover, lack of therapies and rising prevalence of off-label drugs are some of the key factors that are promoting the growth of global scleroderma therapeutics market. Moreover, growing developments in the field…
Scleroderma Therapeutics Market Analysis - Forecast to 2026
As per the research conducted by GME, the Global Scleroderma Therapeutics Market will grow with a CAGR value of 6.1 percent. Moreover, the rising R&D activities along with the advancing technology and increasing government spending in the pharma industry has boosted the market and growth will be seen in the future.
Browse 151 Market Data Tables and 111 Figures spread through 181 Pages and in-depth TOC on “Global Scleroderma Therapeutics Market…
Global Scleroderma Therapeutics Market Size & Growth Analysis Report, 2020-2026
The global scleroderma therapeutics market is anticipated to showcase considerable growth during the forecast period (2020-2026). The rising FDA approvals, rising investment in the R&D of drugs for its treatment, the emergence of new novel therapies, and new product launches are some of the key factors contributing to the growth of the scleroderma therapeutics market across the globe. According to the American College of Rheumatology, scleroderma is a relatively rare…
Scleroderma Therapy Solutions Industry Outlook and Forecast 2020-2025
This report also researches and evaluates the impact of Covid-19 outbreak on the Scleroderma Therapy Solutions industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Scleroderma Therapy Solutions and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).
Global Scleroderma Therapy Solutions Market Overview:
GLOBAL INFO RESEARCH has evaluated the global Scleroderma Therapy Solutions market in its latest research report. The research report,…
Scleroderma Drug Market to Witness Robust Expansion by 2026
Market Research Report Store offers a latest published report on Scleroderma Drug Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
This study mainly helps understand which market segments or Region or Country they should focus in coming years to channelize their efforts and investments to maximize growth and profitability. The report presents the market competitive landscape and a consistent in…
Develop Business Strategies Of Systemic Sclerosis (Scleroderma) Market 2024
"The Latest Research Report OpportunityAnalyzer: Systemic Sclerosis (Scleroderma) - Opportunity Analysis and Forecast to 2024 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
About Systemic Sclerosis (Scleroderma) Market
Systemic sclerosis (SSc) is a complex autoimmune disease that affects the skin and multiple internal organs. Common manifestations of SSc that are included in this report are skin fibrosis, lung fibrosis, and digital vasculopathy (including…
